A Potent Humanized Anti-CD38 Therapeutic, Antibody for Hematologic Malignancies

antibody for hematologic malignancies, including multiple myeloma and … Monoclonal Antibodies in Clinical Oncology and Symposium on Cancer ….. against a variety of cells lines derived from lymphoma, multiple myeloma and leukemia ..

More PDF Content

A Potent Humanized Anti-CD38 Therapeutic, Antibody for Hematologic Malignancies, including multiple myeloma and non-Hodgkin\’s lymphoma
SAR650984 and rituximab showed similar efficacy in a disseminated survival model with Daudi cells * SCID mouse disseminated survival model with Daudi lymphoma cells Schedule: 40 mg/kg of SAR650984 or rituximab twice weekly for 3 weeks starting on day 7 The median survival (range) was 28 days (26-30 days) for PBS, 47 days (40-51 days) for SAR650984, and 42.5 days (40-51 days) for rituximab.

Download A Potent Humanized Anti-CD38 Therapeutic, Antibody for Hematologic Malignancies pdf from www.cancerconferences.org, 19 pages, 224.81KB.